We recently compiled a list of the 10 Best Debt-Free Penny Stocks to Buy Now. In this article, we are going to take a look at where Arbutus Biopharma Corporation (NASDAQ:ABUS) stands against the other debt-free penny stocks to buy.
Inflation in the U.S. has dropped to the lowest level since 2021, setting the stage for the Federal Reserve to cut interest rates. With inflation down to 2.5%, close to the recommended 2%, the prospects of the U.S. Federal Reserve conducting more than one interest rate cut heading into year-end is more than guaranteed.
Investors tend to be excessively hopeful regarding the extent and timing of Federal Reserve rate reductions. The markets are fond of reduced rates as they can boost economic growth by reducing the cost of borrowing for U.S. businesses and individuals.
READ ALSO: 10 Undervalued Cyclical Stocks to Buy According to Analysts and 10 Best US Stocks to Buy Under $5.
The prospect of an interest rate cut of more than 50 basis points before year-end makes the case for being bullish in the equity markets. Penny stocks could be an ideal play on the risk-reward front, given that valuations in the overall market have gotten out of hand.
With the S&P 500 up by more than 17% for the year, large-cap stocks are trading at premium valuations after blockbuster gains over the past year. The artificial intelligence frenzy has catalyzed the blockbuster move to the upside. Nevertheless, debt-free penny stocks are still trading at discounted valuations with tremendous upside potential.
While inflation levels have eased significantly over the past year, it does not mean that prices of things have dropped significantly. According to Lisa Sturtevant, chief economist at Bright MLS, consumers are paying more than 20% more for goods and services than before the pandemic. However, the prospects of lower interest rates should be a boon for companies.
Access to cheap capital should be much easier with the benchmark rate coming down. Penny stocks, mostly made up of low market cap companies, should be the biggest beneficiaries as they could access capital to ramp up operations and fund growth.
Nevertheless, concerns are growing on Wall Street that interest rate reduction might come too late, as numerous American consumers are already struggling to cope with the burden of elevated costs and limited capacity to increase their spending. A wave of disappointing economic data, especially in the labor market, sends jitters that the economy might be slowing.
Jamie Dimon has already reiterated that there is a 30% to 40% chance of the economy plunging into recession. According to Dimon, the long-running high interest rate environment put more pressure on the economy in the run-up to pull inflation down to 2%.
With recession fears gathering steam in recent months, a wave of caution has gripped the equity market as investors remain wary of the elevated valuation. Amid these concerns, the Best Debt Free Penny Stocks to Buy Now offer a way out of the debacle as such companies are well poised to benefit from inflation and interest rates dropping.
American companies continue to have dangerously high debt levels on their financial statements. A report from S&P Global Ratings reveals that the number of corporate debt defaults spiked last year and could see a resurgence in 2024, as companies with limited liquidity face the burden of high interest rates.
In 2023, 153 companies could not fulfill their debt payment commitments, a notable jump from 85 in the prior year, indicating an 80% increase. This represents the highest default rate in seven years, excluding the sharp increase during the COVID-19 pandemic in 2020.
While many U.S. companies boast robust balance sheets, a considerable amount of defaults originate from companies with negative cash flows and high debt levels. Experts label these companies heavily in debt as “zombies,” as they fight to stay afloat, barely able to cover the interest on their debts, and frequently teetering on the brink of collapse. Penny stocks with solid balance sheets and low debt levels offer one of the best ways of diversifying an investment portfolio at highly discounted valuations.
Our Methodology
To make our list of the 10 Best Debt Free Penny Stocks to Buy Now, we used the Yahoo Finance and Finviz stock screeners to find penny stocks with a market cap of over $500 million. Next, we shortlisted the stocks whose enterprise value was less than the market cap and had a debt of less than $50 million. Finally, we ranked these cash-rich stocks in ascending order of the number of hedge funds that have stakes in them, as of Q2 2024.
At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A shot of a laboratory team in lab coats and safety gloves preparing biopharmaceuticals.
Arbutus Biopharma Corporation (NASDAQ:ABUS)
Market Cap as of September 13: $815.54 Million
Enterprise Value: $675.15 Million
Hedge Funds Holding Stakes as of Q2 2024: 15
Arbutus Biopharma Corporation (NASDAQ:ABUS), a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection. It boasts a robust product line that includes imdusiran, which suppresses HBV antigens.
With the stock trading near all-time highs, the rally has come on investors taking note of the company’s tremendous potential backed by its innovative hepatitis B treatments. Its outperformance also indicates investor confidence in its therapeutic pipeline in the healthcare market.
Arbutus Biopharma Corporation (NASDAQ:ABUS) has shared encouraging results from its early-stage trials of its RNAi drug imdusiran, indicating it might be a promising option for treating hepatitis B. The firm intends to start its next phase of clinical trials for imdusiran, supported by its existing cash reserves estimated at around $148.5 million.
Arbutus Biopharma Corporation (NASDAQ:ABUS) exited the second quarter with $148.5 million in cash, enough to finance the development of its pipeline. Arbutus holds more cash than debt on its balance sheet, a positive sign of financial stability. It held about $1.59 million in debt as of the end of June.
The positive clinical trial results and careful handling of assets set the stage for the company to keep its quest for a possible cure for hepatitis B. As the company deals with the intricacies of clinical trials and legal matters, investors and interested parties will eagerly await more information on the advancement of Imdusiran and other projects in development.
As of June 2024, 15 out of the 912 hedge funds profiled by Insider Monkey had held a stake in the company. Arbutus Biopharma Corporation (NASDAQ:ABUS)’s biggest investor is David Salanic’s Whitefort Capital since it owns $39.76 million worth of shares.
Overall ABUS ranks 7th on our list of the best debt-free penny stocks to buy. While we acknowledge the potential of ABUS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ABUS, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.
